Form 4: Acrivon Therapeutics CFO Sells Shares to Cover Tax Obligations

Acrivon Therapeutics' Chief Financial Officer, Rasmus Holm-Jorgensen, sold 368 shares of common stock to cover tax obligations related to vesting restricted stock units.

Summary

• Rasmus Holm-Jorgensen, the Chief Financial Officer of Acrivon Therapeutics, sold 368 shares of common stock on November 14, 2024.
• The sale was executed at a price of $7.92 per share.
• This transaction was to cover mandatory tax withholding requirements upon the vesting of restricted stock units.
• Following the transaction, Mr. Holm-Jorgensen directly owns 26,522 shares of Acrivon Therapeutics common stock.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction for tax purposes, with no indication of positive or negative sentiment.

Industry Context

This is a routine transaction for company executives to cover tax obligations related to stock-based compensation. It is common for executives to sell shares after vesting to cover taxes.

Comparison to Industry Standards

• Form 4 filings are standard practice for publicly traded companies in the US, and this transaction is consistent with typical insider trading activity.
• Many executives at publicly traded companies sell shares to cover tax obligations when stock options or restricted stock units vest.
• The sale of 368 shares is a relatively small transaction and is unlikely to have a significant impact on the stock price.

Stakeholder Impact

• The transaction is unlikely to have a significant impact on shareholders as it is a small sale by an executive to cover tax obligations.

Key Dates

Keywords

Acrivon Therapeutics, Rasmus Holm-Jorgensen, CFO, stock sale, tax withholding, restricted stock units, insider trading, Form 4